Our investment in Bridgit
Investment note announcing the firm's lead of Bridgit's $7.7 million Series A. Covers the bridging-loan fintech's product, traction, market, and founders' backgrounds at Stake, MoneyMe and KPMG.
Company
Every investor coverage indicates participated in a round Orchard raised.
Companies Orchard acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Steven M. Altschuler | Board Member | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Orchard. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Investment note announcing the firm's lead of Bridgit's $7.7 million Series A. Covers the bridging-loan fintech's product, traction, market, and founders' backgrounds at Stake, MoneyMe and KPMG.
Eye-disease drug developer Azura Ophthalmics has appointed healthcare biotech veteran Steven Altschuler, a Ziff Capital Partners managing director and Spark Therapeutics co-founder, as chair of its board.